CD274 and non-small cell lung carcinoma: Immune checkpoint inhibitors (ICIs), particularly those targeting the PD-1/PD-L1 axis, have transformed the therapeutic landscape of non-small cell lung cancer (NSCLC) Programmed death ligand 1 (PD-L1) is a transmembrane protein expressed on tumor cells and infiltrating immune cells.